Evidence map›Paper›PMID 39725974›Full record

ArticleJournal of nanobiotechnology2024

Spatiotemporal-controllable ROS-responsive camptothecin nano-bomb for chemo/photo/immunotherapy in triple-negative breast cancer.

Wenjie Xu, Zhaokui Zeng, Yucheng Tang, Jingjing Tian, Xinyan Hao, Pengcheng Sun, Yanjin Peng, Tian Tian, Daxiong Xiang, Rongrong Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Ethnobotany-guided exploration of plant-derived photosensitizer candidates for photodynamic therapy.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wenjie Xu *Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Zhaokui Zeng *Department of Pharmacy, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410000, China.
Yucheng TangDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Jingjing TianDepartment of Pharmacy, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410000, China.
Xinyan HaoDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Pengcheng SunDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Yanjin PengDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Tian TianDepartment of Pharmacy, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410000, China.
Daxiong XiangDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
Rongrong WangHunan Institute of Drug Inspection, 60 Bayi Road, Changsha, 410001, Hunan, China. 273199683@qq.com.
Chuanpin ChenDepartment of Pharmacy, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410000, China. ccpin2000@hotmail.com.
Junyong WuDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, China. wujunyong@csu.edu.cn.

Funding

China Postdoctoral Science Foundation 2023M733962Joint Innovation Program for Postgraduates of Central South University and Enterprises 2022XQLH103National Natural Science Foundation of China 82373295Natural Science Foundation of Hunan Province 2024JJ4081Postdoctoral Fellowship Program of CPSF, China GZB20230873The Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University QH20230269
6 · The paper itself

Abstract

Chemotherapy is still one of the major approaches in triple-negative breast cancer (TNBC) treatment. The development of new formulations for classic chemotherapeutic drugs remains interests in studies. Camptothecin (CPT) is powerful antitumor agents in TNBC treatment though its clinic applications are limited by its low water solubility and systemic toxicity. To prepare a spatiotemporal controllable CPT nano-formulation, we construct a ROS-responsive self-assembly nanoparticle by combining hydrophobic CPT and hydrophilic 5-floxuridine (FUDR). A ROS-sensitive thioketal (TK) linker is used to prepare CPT-TK-FUDR (CTF). Next, we introduced IR780-based phototherapy to elicit massive ROS regeneration due to the endogenous ROS is not sufficient. IR780 is modified with hyaluronic acid (HA) to prepare HA-modified IR780 (HAIR) for its biocompatibility and tumor targeting ability improvement. CTF and HAIR self-assemble to form an attractive nano-bomb (HAIR/CTF NPs). HA accurately guides the NPs to tumor sites via HA-receptor recognition on tumor cells. After internalization, overexpressed intracellular HAase in tumor cells disassembles the NPs to free the contents. Due to the presence of IR780 molecules, the scheduled irradiation of 808 nm laser induces massive reactive oxygen species (ROS) generation, which further result in the cleavage of TK linker for free drugs release. Additionally, ROS-mediated photodynamic therapy (PDT) and near-infrared laser-mediated photothermal therapy (PTT) synergistically worked to eradicate tumor cells. Then immunogenic cell death (ICD) was evoked by CPT and phototherapy to amplify antitumor immunity, thereby achieving primary and abscopal tumor inhibition. In conclusion, the HAIR/CTF nano-bomb realized spatiotemporal controllable drug release, exciting tumor eradication and attractive anti-metastasis efficacy via combination chemo/photo/immunotherapy, offering a valuable reference for the re-development of classic drug in future clinical practice.

Indexed as

CamptothecinImmunotherapyNanoparticlesPhototherapyReactive Oxygen SpeciesTriple Negative Breast NeoplasmsAnimalsAntineoplastic AgentsCell Line, TumorFemaleHumansHyaluronic AcidIndolesMiceMice, Inbred BALB CMice, Nude2-(2-(2-chloro-3-((1,3-dihydro-3,3-dimethyl-1-propyl-2H-indol-2-ylidene)ethylidene)-1-cyclohexen-1-yl)ethenyl)-3,3-dimethyl-1-propylindoliumAntineoplastic AgentsCamptothecinHyaluronic AcidIndolesReactive Oxygen SpeciesAnti-metastasisCombination therapyICDROS-responsive prodrugSelf-assemblySpatiotemporal-controllable

Identifiers

PMID39725974
PMCPMC11673808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.